{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:02:11Z","timestamp":1789650131764,"version":"4.0.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"crossref","award":["NBCF-13-09"],"award-info":[{"award-number":["NBCF-13-09"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.canlet.2016.11.013","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T03:45:18Z","timestamp":1479354318000},"page":"141-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Adoptive transfer of ex\u00a0vivo expanded V\u03b39V\u03b42 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer"],"prefix":"10.1016","volume":"386","author":[{"given":"Aneta","family":"Zysk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark O.","family":"DeNichilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Panagopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Zinonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Liapis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Ingman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Ponomarev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Findlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Zannettino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Evdokiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2016.11.013_bib1","series-title":"SEER Cancer Statistics Review, 1975\u20132013","year":"2016"},{"key":"10.1016\/j.canlet.2016.11.013_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2016.11.013_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.canlet.2016.11.013_bib4","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2016.11.013_bib5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.canlet.2016.11.013_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.327.7413.469","article-title":"Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer","volume":"327","author":"Ross","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.canlet.2016.11.013_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8040","article-title":"A\u00a0systematic review of the role of bisphosphonates in metastatic disease","volume":"8","author":"Ross","year":"2004","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.canlet.2016.11.013_bib8","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nri797","article-title":"Gammadelta T cells: functional plasticity and heterogeneity","volume":"2","author":"Carding","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2016.11.013_bib9","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/jnci\/83.21.1564","article-title":"Comparison of cytolytic and proliferative activities of human gamma delta and alpha beta T cells from peripheral blood against various human tumor cell lines","volume":"83","author":"Ensslin","year":"1991","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2016.11.013_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cellimm.2007.11.005","article-title":"Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells","volume":"249","author":"Muraro","year":"2007","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.canlet.2016.11.013_bib11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.intimp.2011.01.001","article-title":"IFN-gamma enhances HOS and U2OS cell lines susceptibility to gammadelta T cell-mediated killing through the Fas\/Fas ligand pathway","volume":"11","author":"Li","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2016.11.013_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12185-011-0885-9","article-title":"Targeting myeloma-osteoclast interaction with Vgamma9Vdelta2 T cells","volume":"94","author":"Cui","year":"2011","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.canlet.2016.11.013_bib13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ijc.20987","article-title":"Cytotoxic effects of gammadelta T cells expanded ex\u00a0vivo by a third generation bisphosphonate for cancer immunotherapy","volume":"116","author":"Sato","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2016.11.013_bib14","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00262-007-0279-2","article-title":"Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity","volume":"56","author":"Mattarollo","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2016.11.013_bib15","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-10-3862","article-title":"High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in\u00a0vivo","volume":"71","author":"Benzaid","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.11.013_bib16","doi-asserted-by":"crossref","DOI":"10.3791\/3182","article-title":"Expansion of human peripheral blood gammadelta T cells using zoledronate","author":"Kondo","year":"2011","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.canlet.2016.11.013_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1084\/jem.20021500","article-title":"Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells","volume":"197","author":"Gober","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.canlet.2016.11.013_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/14653249.2011.623693","article-title":"Gamma delta T cells from HIV+ donors can be expanded in\u00a0vitro by zoledronate\/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity","volume":"14","author":"Poonia","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.canlet.2016.11.013_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12865-015-0124-x","article-title":"In\u00a0vitro analysis of the proliferative capacity and cytotoxic effects of ex\u00a0vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells","volume":"16","author":"Niu","year":"2015","journal-title":"BMC Immunol."},{"key":"10.1016\/j.canlet.2016.11.013_bib20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1084\/jem.20030235","article-title":"Differentiation of effector\/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites","volume":"198","author":"Dieli","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.canlet.2016.11.013_bib21","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.4049\/jimmunol.0903454","article-title":"V\u00a0gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells","volume":"184","author":"D'Asaro","year":"2010","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.canlet.2016.11.013_bib22","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/ijc.28217","article-title":"Human Vgamma2Vdelta2 T cells limit breast cancer growth by modulating cell survival-, apoptosis-related molecules and microenvironment in tumors","volume":"133","author":"Aggarwal","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2016.11.013_bib23","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.4049\/jimmunol.1300255","article-title":"Repeated systemic administrations of both aminobisphosphonates and human Vgamma9Vdelta2 T cells efficiently control tumor development in\u00a0vivo","volume":"191","author":"Santolaria","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.canlet.2016.11.013_bib24","doi-asserted-by":"crossref","first-page":"e27572","DOI":"10.4161\/onci.27572","article-title":"Gammadelta T cells for cancer immunotherapy: a systematic review of clinical trials","volume":"3","author":"Fisher","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2016.11.013_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11060-013-1258-4","article-title":"Cytotoxic human peripheral blood-derived gammadeltaT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma","volume":"116","author":"Nakazawa","year":"2014","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1016\/j.canlet.2016.11.013_bib26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00262-011-1021-7","article-title":"Phase I\/II study of adoptive transfer of gammadelta T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma","volume":"60","author":"Kobayashi","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2016.11.013_bib27","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cam4.196","article-title":"Intraperitoneal injection of in\u00a0vitro expanded Vgamma9Vdelta2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer","volume":"3","author":"Wada","year":"2014","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2016.11.013_bib28","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/bjc.2011.293","article-title":"Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours","volume":"105","author":"Nicol","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2016.11.013_bib29","series-title":"Bone cancer: Primary Bone Cancers and Bone Metastases","first-page":"629","article-title":"Bone cancer: primary bone cancers and bone metastases","author":"Kalyan","year":"2014"},{"key":"10.1016\/j.canlet.2016.11.013_bib30","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/1535-7163.MCT-09-0745","article-title":"Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer","volume":"8","author":"Zinonos","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2016.11.013_bib31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.canlet.2014.11.020","article-title":"Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma","volume":"357","author":"Liapis","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2016.11.013_bib32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-009-0527-6","article-title":"Adoptively transferred ex\u00a0vivo expanded gammadelta-T cells mediate in\u00a0vivo antitumor activity in preclinical mouse models of breast cancer","volume":"122","author":"Beck","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2016.11.013_bib33","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1158\/0008-5472.CAN-05-4386","article-title":"Apo2l\/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model","volume":"66","author":"Thai le","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.11.013_bib34","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.bone.2007.12.225","article-title":"Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells","volume":"42","author":"Coxon","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.canlet.2016.11.013_bib35","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.4049\/jimmunol.180.9.6044","article-title":"Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer","volume":"180","author":"Liu","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.canlet.2016.11.013_bib36","article-title":"Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer","author":"Junankar","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2016.11.013_bib37","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/mol.105.020776","article-title":"Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis","volume":"69","author":"Thompson","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.canlet.2016.11.013_bib38","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1359\/jbmr.091009","article-title":"Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in\u00a0vivo","volume":"25","author":"Roelofs","year":"2010","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.canlet.2016.11.013_bib39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2567.2003.01600.x","article-title":"Macrophages exposed to Mycobacterium tuberculosis release chemokines able to recruit selected leucocyte subpopulations: focus on gammadelta cells","volume":"108","author":"Ferrero","year":"2003","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2016.11.013_bib40","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bjc.6603548","article-title":"Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma","volume":"96","author":"Horie","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2016.11.013_bib41","first-page":"233","article-title":"Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents","volume":"24","author":"Koto","year":"2010","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2016.11.013_bib42","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1359\/jbmr.2000.15.11.2211","article-title":"Bisphosphonates induce breast cancer cell death in\u00a0vitro","volume":"15","author":"Fromigue","year":"2000","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.canlet.2016.11.013_bib43","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.11.013_bib44","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.eururo.2004.04.022","article-title":"Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer","volume":"46","author":"Montague","year":"2004","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2016.11.013_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lungcan.2004.06.003","article-title":"Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines","volume":"47","author":"Matsumoto","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2016.11.013_bib46","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3346\/jkms.2011.26.12.1569","article-title":"Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells","volume":"26","author":"Jeong","year":"2011","journal-title":"J.\u00a0Korean Med. Sci."},{"key":"10.1016\/j.canlet.2016.11.013_bib47","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/cncr.21530","article-title":"Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice","volume":"104","author":"Ory","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2016.11.013_bib48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.canlet.2013.07.024","article-title":"Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models","volume":"339","author":"Luo","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2016.11.013_bib49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2008.09.026","article-title":"Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model","volume":"274","author":"Koto","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2016.11.013_bib50","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1158\/1078-0432.CCR-08-1616","article-title":"Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model","volume":"15","author":"Labrinidis","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2016.11.013_bib51","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ijc.25051","article-title":"Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model","volume":"127","author":"Labrinidis","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2016.11.013_bib52","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/jbmr.1769","article-title":"Can peripheral blood gammadelta T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of aminobisphosphonate therapy","volume":"28","author":"Kalyan","year":"2013","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.canlet.2016.11.013_bib53","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/cei.12165","article-title":"Activated gammadelta T cells inhibit osteoclast differentiation and resorptive activity in\u00a0vitro","volume":"174","author":"Pappalardo","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.canlet.2016.11.013_bib54","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.4049\/jimmunol.1100804","article-title":"Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis","volume":"187","author":"Laggner","year":"2011","journal-title":"J.\u00a0Immunol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516306991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516306991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T17:05:43Z","timestamp":1718903143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383516306991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":54,"alternative-id":["S0304383516306991"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2016.11.013","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adoptive transfer of ex\u00a0vivo expanded V\u03b39V\u03b42 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2016.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}